Doses were analysed by multiplying the mean maximum dose at the end of trial with the dosing regime (per administration, per day). As studies were multinational, the international average adult weight was used to calculate dose per day for parenteral routes of administration. To account for differences in bioavailability, the daily doses were multiplied by the reported bioavailabilities for each drug and administration route (SI table 1). To assess pharmacological equivalence, drug doses were normalized to the iloprost dose reported in the McLaughlin et al. 2006 clinical trial and given 1 for both being the lowest molecular weight and the highest Ki at the IP receptor (4 nM). The estimated dose-ratio or all PMs with respect to iloprost is given in the last column 
. Meta-regression for outcomes. 
Meta-Regression Coefficient Standard Error p-Value

